Monopar Therapeutics (MNPR) Projected to Post Earnings on Thursday

Monopar Therapeutics (NASDAQ:MNPR) is projected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Monopar Therapeutics to post earnings of ($0.37) per share for the quarter.

Monopar Therapeutics Price Performance

Shares of MNPR stock opened at $37.58 on Wednesday. The company has a fifty day moving average price of $37.65 and a two-hundred day moving average price of $23.31. The stock has a market cap of $229.31 million, a P/E ratio of -19.08 and a beta of 1.18. Monopar Therapeutics has a one year low of $1.72 and a one year high of $54.30.

Analyst Ratings Changes

Several research firms recently weighed in on MNPR. HC Wainwright lifted their price target on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd. Piper Sandler reaffirmed an “overweight” rating and set a $76.00 price target on shares of Monopar Therapeutics in a report on Wednesday, March 19th.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.